These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 38729446)

  • 41. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy.
    Samuel CS; Hewitson TD; Zhang Y; Kelly DJ
    Endocrinology; 2008 Jul; 149(7):3286-93. PubMed ID: 18388190
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relaxin's induction of metalloproteinases is associated with the loss of collagen and glycosaminoglycans in synovial joint fibrocartilaginous explants.
    Naqvi T; Duong TT; Hashem G; Shiga M; Zhang Q; Kapila S
    Arthritis Res Ther; 2005; 7(1):R1-11. PubMed ID: 15642129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats.
    Yoshida T; Kumagai H; Kohsaka T; Ikegaya N
    Nephron Exp Nephrol; 2014; 128(1-2):9-20. PubMed ID: 25403022
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Characterizing relaxin receptor expression and exploring relaxin's effect on tissue remodeling/fibrosis in the human bladder.
    Diaz EC; Briggs M; Wen Y; Zhuang G; Wallace SL; Dobberfuhl AD; Kao CS; Chen BC
    BMC Urol; 2020 Apr; 20(1):44. PubMed ID: 32321501
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Investigations into the inhibitory effects of relaxin on renal myofibroblast differentiation.
    Samuel CS; Mookerjee I; Halls ML; Summers RJ; Chew E; Bathgate RA; Tregear GW; Hewitson TD
    Ann N Y Acad Sci; 2009 Apr; 1160():294-9. PubMed ID: 19416207
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relaxin: an endogenous renoprotective factor?
    Hewitson TD; Samuel CS
    Ann N Y Acad Sci; 2009 Apr; 1160():289-93. PubMed ID: 19416206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protective role of relaxin in a mouse model of aristolochic acid nephropathy.
    Yang X; Thorngren D; Chen Q; Wang M; Xie X
    Biomed Pharmacother; 2019 Jul; 115():108917. PubMed ID: 31060002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relaxin and the extracellular matrix: molecular mechanisms of action and implications for cardiovascular disease.
    McGuane JT; Parry LJ
    Expert Rev Mol Med; 2005 Sep; 7(21):1-18. PubMed ID: 16191259
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relaxin in cardiovascular and renal disease.
    Samuel CS; Hewitson TD
    Kidney Int; 2006 May; 69(9):1498-502. PubMed ID: 16672919
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relaxin and its role in the development and treatment of fibrosis.
    Bennett RG
    Transl Res; 2009 Jul; 154(1):1-6. PubMed ID: 19524867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical profile of relaxin, a possible new drug for human use.
    Bani D; Yue SK; Bigazzi M
    Curr Drug Saf; 2009 Sep; 4(3):238-49. PubMed ID: 19534649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relaxin attenuates silica-induced pulmonary fibrosis by regulating collagen type I and MMP-2.
    Li XF; Liao J; Xin ZQ; Lu WQ; Liu AL
    Int Immunopharmacol; 2013 Nov; 17(3):537-42. PubMed ID: 23973652
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding relaxin signalling at the cellular level.
    Valkovic AL; Bathgate RA; Samuel CS; Kocan M
    Mol Cell Endocrinol; 2019 May; 487():24-33. PubMed ID: 30592984
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.
    Chow BS; Chew EG; Zhao C; Bathgate RA; Hewitson TD; Samuel CS
    PLoS One; 2012; 7(8):e42714. PubMed ID: 22936987
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of relaxin action in the reproductive tract: studies in the relaxin-deficient (Rlx-/-) mouse.
    Parry LJ; McGuane JT; Gehring HM; Kostic IG; Siebel AL
    Ann N Y Acad Sci; 2005 May; 1041():91-103. PubMed ID: 15956691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of sphingosine kinase/S1P axis in ECM remodeling of cardiac cells elicited by relaxin.
    Frati A; Ricci B; Pierucci F; Nistri S; Bani D; Meacci E
    Mol Endocrinol; 2015 Jan; 29(1):53-67. PubMed ID: 25415609
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serelaxin inhibits the profibrotic TGF-β1/IL-1β axis by targeting TLR-4 and the NLRP3 inflammasome in cardiac myofibroblasts.
    Cáceres FT; Gaspari TA; Samuel CS; Pinar AA
    FASEB J; 2019 Dec; 33(12):14717-14733. PubMed ID: 31689135
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis.
    Hewitson TD; Ho WY; Samuel CS
    Endocrinology; 2010 Oct; 151(10):4938-48. PubMed ID: 20826562
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relaxin reverses inflammatory and immune signals in aged hearts.
    Martin B; Gabris-Weber BA; Reddy R; Romero G; Chattopadhyay A; Salama G
    PLoS One; 2018; 13(1):e0190935. PubMed ID: 29346407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties.
    Beiert T; Knappe V; Tiyerili V; Stöckigt F; Effelsberg V; Linhart M; Steinmetz M; Klein S; Schierwagen R; Trebicka J; Roell W; Nickenig G; Schrickel JW; Andrié RP
    Int J Cardiol; 2018 Jan; 250():21-28. PubMed ID: 29169754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.